Sleeping Beauty-mediated correction of Fanconi anemia type C

Kendra A. Hyland, Erik R. Olson, Karl J. Clark, Elena L. Aronovich, Perry B. Hackett, Bruce R. Blazar, Jakub Tolar, R. Scott Mcivor

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Background: The Sleeping Beauty (SB) transposon system can insert defined sequences into chromosomes to direct the extended expression of therapeutic genes. Our goal is to develop the SB system for nonviral complementation of Fanconi anemia (FA), a rare autosomal recessive disorder accompanied by progressive bone marrow failure. Methods: We used a CytoPulse electroporation system (CytoPulse, Glen Burnie, MD, USA) to introduce SB transposons into human lymphoblastoid cells (LCL) derived from both Fanconi anemia type C (FA-C) defective and normal patients. Correction of the FA-C defect was assessed by resistance to mitomycin C, a DNA-crosslinking agent. Results: Culture of both cell types with the antioxidant N-acetyl- l-cysteine improved cell viability after electroporation. Co-delivery of enhanced green fluorescent protein (GFP) transposon with SB100X transposase-encoding plasmid supported a 50- to 90-fold increase in stable GFP expression compared to that observed in the absence of SB100X for normal LCL, but in FA-C defective LCL SB100X enhancement of stable GFP-expression was a more moderate five- to 13-fold. SB-mediated integration and expression of the FA-C gene was demonstrated by the emergence of a mitomycin C-resistant population bearing characteristic transposon-chromosome junction sequences and exhibiting a mitomycin dose response identical to that of normal LCL. Conclusions: The SB transposon system achieved stable expression of therapeutic FA-C genes, complementing the genetic defect in patient-derived cells by nonviral gene transfer.

Original languageEnglish (US)
Pages (from-to)462-469
Number of pages8
JournalJournal of Gene Medicine
Volume13
Issue number9
DOIs
StatePublished - Sep 1 2011

Fingerprint

Fanconi Anemia
Beauty
Mitomycin
Electroporation
Green Fluorescent Proteins
Chromosomes
Genes
Transposases
Population Characteristics
Cysteine
Cell Survival
Plasmids
Cell Culture Techniques
Antioxidants
Bone Marrow
Gene Expression
DNA
Therapeutics

Keywords

  • Fanconi anemia
  • Gene therapy
  • Nonviral
  • Sleeping Beauty

Cite this

Sleeping Beauty-mediated correction of Fanconi anemia type C. / Hyland, Kendra A.; Olson, Erik R.; Clark, Karl J.; Aronovich, Elena L.; Hackett, Perry B.; Blazar, Bruce R.; Tolar, Jakub; Scott Mcivor, R.

In: Journal of Gene Medicine, Vol. 13, No. 9, 01.09.2011, p. 462-469.

Research output: Contribution to journalArticle

@article{955c1195242a49c3920ff9376504ef4d,
title = "Sleeping Beauty-mediated correction of Fanconi anemia type C",
abstract = "Background: The Sleeping Beauty (SB) transposon system can insert defined sequences into chromosomes to direct the extended expression of therapeutic genes. Our goal is to develop the SB system for nonviral complementation of Fanconi anemia (FA), a rare autosomal recessive disorder accompanied by progressive bone marrow failure. Methods: We used a CytoPulse electroporation system (CytoPulse, Glen Burnie, MD, USA) to introduce SB transposons into human lymphoblastoid cells (LCL) derived from both Fanconi anemia type C (FA-C) defective and normal patients. Correction of the FA-C defect was assessed by resistance to mitomycin C, a DNA-crosslinking agent. Results: Culture of both cell types with the antioxidant N-acetyl- l-cysteine improved cell viability after electroporation. Co-delivery of enhanced green fluorescent protein (GFP) transposon with SB100X transposase-encoding plasmid supported a 50- to 90-fold increase in stable GFP expression compared to that observed in the absence of SB100X for normal LCL, but in FA-C defective LCL SB100X enhancement of stable GFP-expression was a more moderate five- to 13-fold. SB-mediated integration and expression of the FA-C gene was demonstrated by the emergence of a mitomycin C-resistant population bearing characteristic transposon-chromosome junction sequences and exhibiting a mitomycin dose response identical to that of normal LCL. Conclusions: The SB transposon system achieved stable expression of therapeutic FA-C genes, complementing the genetic defect in patient-derived cells by nonviral gene transfer.",
keywords = "Fanconi anemia, Gene therapy, Nonviral, Sleeping Beauty",
author = "Hyland, {Kendra A.} and Olson, {Erik R.} and Clark, {Karl J.} and Aronovich, {Elena L.} and Hackett, {Perry B.} and Blazar, {Bruce R.} and Jakub Tolar and {Scott Mcivor}, R.",
year = "2011",
month = "9",
day = "1",
doi = "10.1002/jgm.1589",
language = "English (US)",
volume = "13",
pages = "462--469",
journal = "Journal of Gene Medicine",
issn = "1099-498X",
publisher = "John Wiley and Sons Ltd",
number = "9",

}

TY - JOUR

T1 - Sleeping Beauty-mediated correction of Fanconi anemia type C

AU - Hyland, Kendra A.

AU - Olson, Erik R.

AU - Clark, Karl J.

AU - Aronovich, Elena L.

AU - Hackett, Perry B.

AU - Blazar, Bruce R.

AU - Tolar, Jakub

AU - Scott Mcivor, R.

PY - 2011/9/1

Y1 - 2011/9/1

N2 - Background: The Sleeping Beauty (SB) transposon system can insert defined sequences into chromosomes to direct the extended expression of therapeutic genes. Our goal is to develop the SB system for nonviral complementation of Fanconi anemia (FA), a rare autosomal recessive disorder accompanied by progressive bone marrow failure. Methods: We used a CytoPulse electroporation system (CytoPulse, Glen Burnie, MD, USA) to introduce SB transposons into human lymphoblastoid cells (LCL) derived from both Fanconi anemia type C (FA-C) defective and normal patients. Correction of the FA-C defect was assessed by resistance to mitomycin C, a DNA-crosslinking agent. Results: Culture of both cell types with the antioxidant N-acetyl- l-cysteine improved cell viability after electroporation. Co-delivery of enhanced green fluorescent protein (GFP) transposon with SB100X transposase-encoding plasmid supported a 50- to 90-fold increase in stable GFP expression compared to that observed in the absence of SB100X for normal LCL, but in FA-C defective LCL SB100X enhancement of stable GFP-expression was a more moderate five- to 13-fold. SB-mediated integration and expression of the FA-C gene was demonstrated by the emergence of a mitomycin C-resistant population bearing characteristic transposon-chromosome junction sequences and exhibiting a mitomycin dose response identical to that of normal LCL. Conclusions: The SB transposon system achieved stable expression of therapeutic FA-C genes, complementing the genetic defect in patient-derived cells by nonviral gene transfer.

AB - Background: The Sleeping Beauty (SB) transposon system can insert defined sequences into chromosomes to direct the extended expression of therapeutic genes. Our goal is to develop the SB system for nonviral complementation of Fanconi anemia (FA), a rare autosomal recessive disorder accompanied by progressive bone marrow failure. Methods: We used a CytoPulse electroporation system (CytoPulse, Glen Burnie, MD, USA) to introduce SB transposons into human lymphoblastoid cells (LCL) derived from both Fanconi anemia type C (FA-C) defective and normal patients. Correction of the FA-C defect was assessed by resistance to mitomycin C, a DNA-crosslinking agent. Results: Culture of both cell types with the antioxidant N-acetyl- l-cysteine improved cell viability after electroporation. Co-delivery of enhanced green fluorescent protein (GFP) transposon with SB100X transposase-encoding plasmid supported a 50- to 90-fold increase in stable GFP expression compared to that observed in the absence of SB100X for normal LCL, but in FA-C defective LCL SB100X enhancement of stable GFP-expression was a more moderate five- to 13-fold. SB-mediated integration and expression of the FA-C gene was demonstrated by the emergence of a mitomycin C-resistant population bearing characteristic transposon-chromosome junction sequences and exhibiting a mitomycin dose response identical to that of normal LCL. Conclusions: The SB transposon system achieved stable expression of therapeutic FA-C genes, complementing the genetic defect in patient-derived cells by nonviral gene transfer.

KW - Fanconi anemia

KW - Gene therapy

KW - Nonviral

KW - Sleeping Beauty

UR - http://www.scopus.com/inward/record.url?scp=80053406954&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053406954&partnerID=8YFLogxK

U2 - 10.1002/jgm.1589

DO - 10.1002/jgm.1589

M3 - Article

VL - 13

SP - 462

EP - 469

JO - Journal of Gene Medicine

JF - Journal of Gene Medicine

SN - 1099-498X

IS - 9

ER -